On June 18, 2026 Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL gene silencing technology to eliminate cancer, reported that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company’s INTASYL siRNA platform, including its lead clinical candidate PH-762 for the treatment of cutaneous carcinomas. The presentation will conclude with a live question and answer session, providing attendees the opportunity to engage directly. In addition, Mr. Bitterman will be available for one-on-one meetings on June 24-25, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We look forward to participating in the Life Sciences Investor Forum, where we will discuss why we believe INTASYL represents a differentiated and promising approach in immuno-oncology," said Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals.

One-on-One Meetings: Phio’s availability is June 24-25, 2026

Phio’s Presentation and live Q&A : Thursday June 25, 2026, at 3 PM EDT

REGISTER HERE: Phio Pharmaceuticals Corp. (NASDAQ: PHIO)

The event will be conducted as a live, interactive online forum, offering investors and industry professionals within the life sciences community the opportunity to submit questions to management in real time. A replay of the webcast will be available following the conclusion of the conference.

It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.

Learn more about the event at www.virtualinvestorconferences.com.

(Press release, Phio Pharmaceuticals, JUN 18, 2026, View Source [SID1234668800])

On June 18, 2026 Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor, reported that it will present a Trial-in-Progress poster at the ESMO (Free ESMO Whitepaper) Gynaecological Cancers Congress 2026, held June 17–19 in Copenhagen, Denmark.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster outlines the scientific background, study design, and clinical rationale for the Company’s ongoing Phase 2 trial evaluating stenoparib in patients with advanced platinum-resistant or platinum-ineligible ovarian cancer. The study builds directly on Allarity’s prior Phase 2 clinical experience, including the durable clinical benefit observed in heavily pretreated ovarian cancer patients. As a Trial-in-Progress presentation, the poster describes the study design and clinical rationale but cannot include new clinical data.

The poster will be presented by the study’s Principal Investigator, Kathleen N. Moore, M.D., an internationally recognized specialist in gynecologic oncology and a leading expert in advanced platinum-resistant and platinum-refractory ovarian cancer. Dr. Moore is also a featured speaker during the congress, which brings together leading international clinical investigators focused on advancing treatment for patients with gynecological cancers.

Poster presentation

Title: 166TiP – NCT03878849: A phase II trial of stenoparib/2X-121, a novel dual inhibitor of PARP and the WNT pathway, in platinum resistant/ineligible ovarian cancer patients
Session: Poster display session
Presenter: Kathleen N. Moore, M.D. (Omaha, United States)
Date: Thursday, June 18, 2026
Location: Exhibition
"Presenting this Trial-in-Progress poster at the ESMO (Free ESMO Whitepaper) Gynaecological Cancers Congress places our ongoing Phase 2 study before the most focused and relevant audience for gynecologic oncology in the U.S. and Europe," said Thomas Jensen, Chief Executive Officer of Allarity Therapeutics. "For Allarity, this is an important opportunity to highlight the clinical rationale and design of our stenoparib study, while beginning to frame the potential role our drug-specific DRP patient selection approach may play in addressing advanced platinum-resistant or platinum-ineligible ovarian cancer for this highly specialized audience. Across both Europe and the U.S., this patient population is recognized as having an urgent need for new, more tolerable treatment options. We are particularly pleased that the poster will be presented by our Principal Investigator, Dr. Kathleen N. Moore, whose expertise in gynecologic oncology is widely recognized and highly valuable as we continue to advance stenoparib toward its next clinical milestones."

The poster will be available on the Company’s website under the Scientific Publications section following its presentation on June 18, 2026.

About Stenoparib/2X-121
Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the WNT signaling pathway. Aberrant WNT/β-catenin signaling has been implicated in the development and progression of numerous cancers, especially drug-resistant cancers. By inhibiting PARP and blocking WNT pathway activation, stenoparib’s unique therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer, small cell lung cancer and colorectal cancer. Allarity has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and 2X-121. Allarity has completed its first Phase 2 trial for stenoparib in advanced ovarian cancer patients. That trial showed promising and durable clinical benefit ovarian cancer patients who had 2+ lines of therapy were enrolled on stenoparib and given drug twice daily. The updated data from this study were presented at the AACR (Free AACR Whitepaper) special conference on advances in ovarian cancer in September 2025. Note that, as these data are from an ongoing trial, analyses may change as the study fully matures. A new protocol was designed expressly to capitalize on this emerging clinical experience with stenoparib in platinum resistant patients and began enrolling patients in the summer of 2025. This amended protocol enrolls only platinum resistant or platinum-ineligible patients and is designed to accelerate the clinical development of stenoparib toward FDA approval. In parallel, a separate Phase 2 trial evaluating stenoparib in combination with temozolomide for relapsed small cell lung cancer (SCLC) began enrolling patients in early 2026 and is currently enrolling patients across multiple VA sites in the US.

About the Drug Response Predictor – DRP Companion Diagnostic
Allarity uses its drug-specific DRP to select those patients who, by the gene expression signature of their cancer, may have a high likelihood of benefiting from a specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit rate may be enhanced. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA expression profiles from patient biopsies. The DRP platform has shown an ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients across dozens of clinical studies (both retrospective and prospective). The DRP platform, which may be useful in all cancer types and is patented for dozens of anti-cancer drugs, has been extensively published in the peer-reviewed literature.

(Press release, Allarity Therapeutics, JUN 18, 2026, View Source [SID1234668799])

On June 18, 2026 Voro Therapeutics, a biotechnology company developing tumor-activated biologics designed to improve the therapeutic index of immune therapies and Alloy Therapeutics, a biotechnology ecosystem company dedicated to empowering the global biologics community, reported a strategic research collaboration focused on the discovery and development of next-generation masked T-cell engager (TCE) therapeutics.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The collaboration combines Voro’s proprietary tumor-activated biologics platform and experience in T-cell engager development with Alloy’s optimized CD3 antibodies and multispecific engineering expertise to develop novel immunotherapies designed to selectively activate immune responses within the tumor microenvironment while minimizing activity in healthy tissues.

TCEs have demonstrated significant therapeutic potential across a broad range of cancers but are often limited by systemic toxicities associated with widespread immune activation. Through this collaboration, Voro and Alloy aim to advance novel approaches that may improve the therapeutic index of TCE therapies, potentially enabling broader clinical utility and expanding the reach of immune-based cancer treatments.

"T-cell engagers have shown tremendous promise, but their broader impact has been constrained by the same challenge facing many powerful immune therapies: how to deliver potency without unacceptable systemic toxicity," said Ugur Eskiocak, Ph.D., Co-Founder and CEO of Voro Therapeutics. "We believe tumor-activated T-cell engagers represent the next evolution of the field. By combining Voro’s PrimeBody platform and TCE design expertise with Alloy’s discovery and multispecific engineering capabilities, we aim to create highly potent, tumor-selective therapies that broaden access for patients."

"We are excited to collaborate with Voro as they apply their innovative tumor-activated biologics platform to address important challenges in immuno-oncology. By integrating Voro’s differentiated linker and masking technologies with Alloy’s optimized CD3 antibodies and cell engager engineering expertise, we can accelerate the development of next-generation TCE’s with potentially best-in-class safety and efficacy. Partnerships like this demonstrate how Alloy’s discovery ecosystem can help enable the next generation of therapeutic innovation," said Mike Schmidt, CSO of Alloy Therapeutics.

This collaboration reflects a shared commitment to advancing innovative biologics and generating novel therapeutic approaches that expand the applicability of T-cell engager therapies, while further strengthening Voro’s growing ecosystem of strategic partners.

(Press release, Voro Therapeutics, JUN 18, 2026, View Source [SID1234668798])

On June 18, 2026 RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, reported that it has entered into a definitive agreement for the purchase and sale of an aggregate of 8,571,429 American Depositary Shares ("ADSs") (or ADS equivalents in lieu thereof), each ADS representing ten thousand (10,000) ordinary shares of the Company, series A-1 warrants to purchase up to an aggregate of 8,571,429 ADSs and series A-2 warrants to purchase up to an aggregate of 8,571,429 ADSs, at a combined purchase price of $0.70 per ADS (or ADS equivalent in lieu thereof) and accompanying warrants in a private placement. The Series A-1 warrants have an exercise price of $0.86 per ADS, are exercisable immediately and have a term of five years following the Effectiveness Date (as defined below), and the Series A-2 warrants have an exercise price of $0.70 per ADS, are exercisable immediately and have a term of 18 months following the Effectiveness Date. The private placement is expected to close on June 22, 2026, subject to the satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The gross proceeds to the Company from this offering are expected to be approximately $6 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the series A-1 warrants and the series A-2 warrants, if fully exercised on a cash basis, will be approximately $13.4 million. No assurance can be given that any of the series warrants will be exercised, or that the Company will receive cash proceeds from the exercise of the series warrants.

The Company intends to use a portion of the net proceeds to support a potential strategic product acquisition and the balance for working capital, research and development and general corporate purposes.

No definitive acquisition agreement has been executed, and any such transaction would remain subject to completion of definitive documentation, financing and other customary conditions. There can be no assurance that any such transaction will be completed.

The securities described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and/or Regulation D promulgated thereunder and, along with the ordinary shares of the Company represented by ADSs underlying the warrants, have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities issued in the private placement and ordinary shares of the Company represented by ADSs underlying the warrants may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to a registration rights agreement with the investors, the Company has agreed to file a resale registration statement covering the securities described above (such date of effectiveness of the resale registration statement, the "Effectiveness Date").

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

(Press release, RedHill Biopharma, JUN 18, 2026, View Source [SID1234668797])

On June 18, 2026 AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") reported that the final subject has received their first dose in the Phase 2 DURIPANC clinical trial evaluating Ampligen (rintatolimod) in combination with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) for the treatment of metastatic pancreatic cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

With this final subject, Primary Endpoint analysis is anticipated to begin in December 2026 and topline results are anticipated in Q1 2027. DURIPANC’s primary endpoint is Clinical Benefit Rate ("CBR"), defined as the proportion of patients achieving stable disease, partial response or complete response at 24 weeks following initiation of combination therapy.

Analysis of Secondary Endpoints is expected to begin in June 2027, or 49 weeks after this final subject received their first dose. DURIPANC’s Secondary Endpoints include Overall Survival ("OS") – the gold standard in oncology trials – as well as progression-free survival and immune profiling analysis that could potentially help identify subsets of future pancreatic cancer patients likely to experience the best survival results, which could be critical to the design of a pivotal Phase 3 clinical trial.

AIM Chief Executive Officer Thomas K. Equels stated: "AIM hopes to utilize the exploratory biomarker data generated through DURIPANC to design a Phase 3 study involving Ampligen in the treatment of pancreatic cancer. We are particularly interested in evaluating whether specific biomarkers may help to identify ‘super-responder’ patient subsets most likely to benefit from Ampligen-based therapy, thus supporting a more targeted and personalized treatment approach."

DURIPANC is a follow-up to the AIM/Erasmus Medical Center Named Patient Program utilizing Ampligen as a monotherapy in late-stage pancreatic cancer, where data suggested impressive improvements in survival, particularly when broken down by biomarker stratifications:

Based upon stratification for immune marker Neutrophil/Lymphocyte ratios less than 4.5, Progression-Free Survival ("PFS") of 17.7 months compared to 8.6 months for historical controls, for an improvement of 9.1 months in PFS
Based upon stratification for immune marker Neutrophil/Lymphocyte ratios less than 4.5, OS of 34.8 months compared to 12.5 months for historical controls, for an improvement of 22.3 months in OS
Based upon stratification for immune marker CA 19-9 less than 1000, PFS of 13.1 months compared to 8.6 months for historical controls, for an improvement of 4.5 months in PFS
Based upon stratification for immune marker CA 19-9 less than 1000, OS of 24.1 months compared to 12.5 months for historical controls, for an improvement of 11.6 months in OS
These results were accompanied by consistent reports of improved quality of life.

About DURIPANC

DURIPANC is an investigator-initiated, exploratory, open-label, single-center Phase 2 study. The clinical trial is a joint collaboration between AIM, AstraZeneca and Erasmus Medical Center in the Netherlands. In addition to the Primary Endpoint of clinical benefit rate, the secondary/exploratory objectives include assessing overall survival (OS) and progression-free survival (PFS); exploring immune-monitoring using available tissue biopsies and peripheral immune profiling; and assessing quality of life.

Read more about the DURIPANC study at ClinicalTrials.gov NCT05927142.

(Press release, AIM ImmunoTech, JUN 18, 2026, View Source [SID1234668796])